Nordic Pharma to Present Breakthrough Dry Eye Therapy at ASCRS Annual Meeting

Introduction

Nordic Pharma, a subsidiary of Nordic Group B.V., is set to present innovative findings related to their dry eye treatment, Lacrifill® Canalicular Gel, during the upcoming Annual Meeting of the American Society of Cataract and Refractive Surgery (ASCRS) from April 25 to 28, 2025, in Los Angeles, California. This gathering is a significant platform where ophthalmic professionals come together to discuss the latest advancements and innovations in eye care.

Clinical Evidence

Recent publications focus on a case study titled "Better Visual Outcomes with Lacrifill® Canalicular Gel-Assisted Ocular Surface Optimization" by Dr. Neel Desai and Dr. Subhashini Chandrasekaran, which demonstrates remarkable improvements in visual acuity and optical quality in patients experiencing fluctuating vision after cataract surgery. Their research highlights how the use of Lacrifill’s gel aids in tear duct occlusion, thereby significantly alleviating dry eye symptoms.

Additionally, the May issue of Cataract Refractive Surgery Today (CRST) will feature results from a patient experience survey among both first-time and returning users of Lacrifill. Impressively, 98.11% of participants indicated a willingness to use Lacrifill again, showcasing high levels of satisfaction and the gel’s effectiveness in addressing dry eye issues.

Impact on Practices

Dr. Jai Parekh, the Commercial Director of Eye Care U.S. at Nordic Pharma, expressed excitement about sharing these clinical findings with attendees at ASCRS 2025. He noted that a year after its launch, Lacrifill® Gel has made a significant impact on clinicians and patients alike, offering a new approach to managing dry eye syndrome. Dr. Parekh emphasized how these results reflect the potential of Lacrifill® to revolutionize patient care in ophthalmology.

Expert Experiences

Among the speakers at the event, Dr. Priya Mathews from the Center for Sight is poised to share her firsthand experiences using Lacrifill with her patients. Dr. Mathews will provide insights into practical benefits and the transformation in patient experiences, referring to herself and others as 'Lacrifillers', a term that embodies those using this innovative gel.

Community Support Initiatives

Visitors to Nordic Pharma's booth (number 717) at ASCRS will also have a unique opportunity to recognize the commendable efforts of firefighters who battled the recent California wildfires. Nordic Pharma is offering a QR code for attendees to donate to the Los Angeles Fire Department Foundation, demonstrating their commitment to community engagement and support. Notably, the company will match donations to amplify the contributions made during this initiative.

About Nordic Pharma

Nordic Group B.V. is a mid-sized international pharmaceutical company focused on specialty products. Its growth strategy includes targeted developments and strategic acquisitions in key areas such as ocular care, rheumatology, and women's health. Expanding beyond Europe, Nordic Group has made significant strides globally, establishing a robust presence and bolstering their market offerings.

Conclusion

As the ASCRS Annual Meeting approaches, all eyes will be on Nordic Pharma to hear their latest updates on Lacrifill® Canalicular Gel. The dual focus on enhancing clinical practice and community involvement sets a compelling narrative for this forward-thinking company. For further information on Lacrifill and to explore ordering details, one can visit lacrifill.com.